Company intelligence / Profile preview

Genix Pharmaceuticals

Vancouver, British Columbia, Canada

Ownership: Private
Employees: ~4000
Development stage: Other

Overview

Genix Pharmaceuticals' core ophthalmic generic drug portfolio is awaiting regulatory clearance for market entry in Canada; two nutraceutical products (Sucanon® for blood sugar and Rechlor® for kidney support) have obtained Health Canada market authorization and are available commercially. Novel ophthalmic drugs, including eyedrops for age-related macular degeneration, are in development but not yet in clinical trials or commercial stage[2][3][6].

Therapeutic areas: NephrologyInfectious DiseasesOphthalmologyEndocrinology
Modalities: Small moleculeHerbal productNutraceuticalBiologic
Industry: Biotech

Partnerships

Canagen Pharmaceuticals (acquisition/licensing of 30 generic ophthalmic drug dossiers)[3]

Beyond the preview

Go deeper on Genix Pharmaceuticals.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Genix Pharmaceuticals.

Explore the full profile